Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01854047 · ClinicalTrials.gov registry record · Phase 2
An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 776
- Enrollment target
NCT01854047 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 776 participants.
The verdict
NCT01854047, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 776 participants
- Enrollment target
Study Summary
Primary Objective: To evaluate the efficacy of different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma. Secondary Objective: To evaluate different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma, with regard to: * Safety and tolerability * Dupilumab systemic exposure and anti-drug antibodies
Interventions
- DRUG placebo
- DRUG Dupilumab
- DRUG ICS/LABA therapy
- DRUG Salbutamol/albuterol
- DRUG Levosalbutamol/levalbuterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 776 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01854047
The ClinicalTrials.gov registry entry for NCT01854047 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 776 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which placebo is the first listed.
NCT01854047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01854047 about?
NCT01854047 is a clinical study titled "An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma". Primary Objective: To evaluate the efficacy of different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma. Secondary Objective: To evaluate different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma, with regard...
What is the current status of trial NCT01854047?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 776 participants. The study started on 2013-06. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01854047?
The interventions under investigation include: placebo (DRUG), Dupilumab (DRUG), ICS/LABA therapy (DRUG), Salbutamol/albuterol (DRUG), Levosalbutamol/levalbuterol (DRUG).
Who is sponsoring clinical trial NCT01854047?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.